Zimmer Biomet (NYSE:ZBH) PT Raised to $140.00 at Stifel Nicolaus

Zimmer Biomet (NYSE:ZBHGet Rating) had its price objective lifted by Stifel Nicolaus from $130.00 to $140.00 in a research note published on Tuesday morning, The Fly reports.

A number of other research analysts have also recently commented on ZBH. Zacks Investment Research raised Zimmer Biomet from a sell rating to a hold rating and set a $133.00 target price on the stock in a research note on Wednesday, April 13th. StockNews.com cut Zimmer Biomet from a buy rating to a hold rating in a research note on Friday, April 8th. Loop Capital cut Zimmer Biomet from a buy rating to a hold rating and set a $130.00 target price on the stock. in a research note on Wednesday, March 2nd. Truist Financial cut Zimmer Biomet from a buy rating to a hold rating and upped their target price for the company from $128.00 to $142.00 in a research note on Wednesday, April 13th. Finally, JMP Securities cut their target price on Zimmer Biomet from $175.00 to $145.00 and set an outperform rating on the stock in a research note on Tuesday, February 8th. Two equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Hold and an average target price of $144.00.

Shares of ZBH stock opened at $120.68 on Tuesday. Zimmer Biomet has a 1 year low of $108.47 and a 1 year high of $176.06. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.41 and a quick ratio of 0.72. The stock’s 50 day simple moving average is $124.27 and its two-hundred day simple moving average is $127.10. The company has a market cap of $25.26 billion, a PE ratio of 63.52, a price-to-earnings-growth ratio of 3.17 and a beta of 1.16.

Zimmer Biomet (NYSE:ZBHGet Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.21. Zimmer Biomet had a return on equity of 12.30% and a net margin of 5.12%. The business had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. Equities research analysts expect that Zimmer Biomet will post 6.52 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 29th. Shareholders of record on Tuesday, March 29th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 28th. This represents a $0.96 annualized dividend and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 50.53%.

In other news, VP Chad F. Phipps sold 35,149 shares of the stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $121.97, for a total transaction of $4,287,123.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.73% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of ZBH. Amplius Wealth Advisors LLC purchased a new position in Zimmer Biomet in the 4th quarter worth $26,000. Cyrus J. Lawrence LLC purchased a new position in Zimmer Biomet in the 1st quarter worth $27,000. Widmann Financial Services Inc. purchased a new position in Zimmer Biomet in the 4th quarter worth $28,000. HHM Wealth Advisors LLC raised its stake in Zimmer Biomet by 84.0% in the 1st quarter. HHM Wealth Advisors LLC now owns 219 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 100 shares during the last quarter. Finally, FSB Premier Wealth Management Inc. purchased a new position in Zimmer Biomet in the 4th quarter worth $33,000. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Zimmer Biomet Company Profile (Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Featured Stories

The Fly logo

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.